So L-dopa can be metabolized inside our body into dopamine.

It is the most effective drug to treat this disease nowaday.

So the principle is very simple.

If the neuron that are responsible for

making dopamine die, then you simply put back dopamine.

That will improve the symptom.

The disadvantage or the side effect of this drug is

only small portion of this drug can cross the blood-brain barrier.

And then the remaining part, the major part of this drug

remains in the other sites of the body.

So there are lots of side effects induced by this drug

including nauseous and stiffness.

And the other major disadvantage of this drug is

because loss of dopaminergic neuron in the substantia nigra died already and

then you try to put in L-dopa to rescue the phenotype.

And then the still alive dopaminergic neuron in that brain region

will sense this exogenous L-dopa and

then it will tell the brain now we have enough dopa.

So the still alive dopaminergic neurons now stop making dopamine.

So itâs just like a feedback loop and it will make the things worse.

So in the patients taking this drug we often see on stage and off state.

The on state is when you take the drug and

then the drug is effective we call it on state.

The off state is no matter how much you take the drug we don't see

effective effect of this drug, so you can have on and off state.

And we have other similar drugs.

One is dopamine agonists.

It's not dopamine, it's not dopamine itself.

It can act on the dopamine receptors and

then can agonist improve the of dopamine receptors.

And the dopamine is synthesized,

is metabolized,

is degraded by the MAO-B enzyme.

So if you use the MAO-B inhibitors to decrease the degradation of dopamine,

then we can kind of improve the symptom as well.

And also there are suggestions for genes therapy, but

this has not been used in clinic yet, it's just in the trial.

And also people suggest some trophic factors,

some growth factors can be protective or can be beneficial for this disease.

For example, the GDNF can improve the symptom in the disease.

And also there are fancy suggestions for transplant, neuronal transplantations.

We transplant some healthy dopaminergic cells,

neurons, to that brain region or

we induce neurons from the stem cell,

neuronal stem cell in that brain region.

These are also trials as well.

These therapies are not widely used in clinic yet.

And then the other thing used in practice is deep brain stimulation.

As we said, L-dopa can have lots of side effect, and

the patient normally have on state and off state.

So during off state, when patients are not responsive to L-dopa at all,

then the clinicians can use this deep brain stimulation instead.

So the principle of this deep brain stimulation is put

in a electrode into the substantia nigra region and

then give a electrical shock in that brain region.

So this is the picture, this is the skull, this is the head of the patient.

You put in a electrode down to that midbrain region,

and then with the stimulator you can give

electric shock directly in that brain region.

And in that brain region, we have lots of dopaminergic neurons, so

by that electrical shock we stimulate a group of neurons together,

and then during that shock, dopaminergic neuron can

release a huge amount of dopamine within that shock area.

That could be effective for,

one deep brain stimulation can last for about one month.

So after one month the patient needs to go back again and then receive another shock.

And because in the deep brain stimulation, we use electric shock,

we use an electrical stimulation.

So in that brain area, in that substantia nigra brain area,

we don't only have dopaminergic neurons.

We also have lots of excitatory neuron and

other neurons like GABAergic neurons or serotonin neurons.

So if you use electrical shock,

you stimulate all the neurons in one brain region.

So we have side effect of overactivate excitatory neurons.

To overcome that, so now we have

another tool we called optogenetics.

The protocol we use now is developed by Dr.

Karl Deisseroth in 2005.

So the principle of this technique is, use these two channels

origined from algae and

these channels can respond to

different wavelengths of light.

For example, this channel here, called ChR2,

this channel can respond to the blue light.

And then when blue light shine on this channel, this channel can open and

then the sodium ion can go in, the potassium ion can go out.

This is not an ion channel, this is a transporter.

And then when this transporter was shine with this yellow light here,

and then this transporter will be activated and it will transport

chlorine ion from outside of the cell to inside of the cell.

So the effect of this two channel activation are totally opposite.

When this ChR2 channel is activated,

it can depolarize the cell.

And when this NpHR is activated, it can hyperpolarize the cell, right?

So Karl, very smartly, put these

channels onto the surface of neuron.

And to activate this ChR2, it's just equal to activate the neuron,

depolarize the neuron and then make the neuron activate.

And in this channel, NpHR, is to used to hyperpolarize

the cell, to make the neuron inactive.

So basically with these two channels or transporters,

people can control the activation of certain group of

neurons by the blue light or yellow light.

And the advantage of this system is these two proteins can be genetically coded.

So by manipulating the promoter of these genetic expression vectors,

we can specifically express these proteins in certain group of neurons.

For example, if I just want to activate dopaminergic neurons,

then I can use this ChR2.

So for example, if I want to activate only

dopaminergic neurons in certain brain area, so

I can put in this ChR2 protein expression vector

only under the dopaminergic promoter, the specific promoter.

So the ChR2, only this protein, will only be expressed in dopaminergic neurons.

When I shine light in these certain brain areas,

then all the neurons will receive the light, but

only the dopaminergic neuron surface would express this channel, this ChR2.

So only the dopaminergic neuron will be activated upon the light.

So this is the actual picture happened in a mouse brain using optogenetics.

So this is the optic fiber that would deliver light here.

And then this is a schematic drawing of a brain area that transfected with ChR2.

So the red neuron indicate the neurons with ChR2 and

then the black neuron are the neurons without this ChR2 protein.

So when light is delivered here, only the red neurons,

only the neurons with ChR2, can be activated by this light,

and the black neurons are not affected.

This is the picture in Karl Deisseroth's paper.

That one there's top panel is

the action potential recorded with

the electrical stimulation.

And then the bottom panel, the blue dot there

shows the point they turn on the blue light.

And then you can see from the each blue light

stimulation we can have the activation of neurons,

just as you stimulate with electric signals.

So compared to the traditional electrical stimulation,

optical stimulation because you can genetically

code the expression of your ion channels, so

you can have specific effect in the target neuronal group not in all area.

And then compare to the drug, you can see in this brain

region if I just want to activate dopaminergic neuron,

I can use dopamine receptor agonist to mimic this effect.

But the advantage of optical genetics compared to drug treatment is

it's reversible very quickly.

For the drug, if you put in certain brain area and

you want to wash it out, at least it will take half an hour to wash out the effect.

But for this protocol you just need to turn off the light.

Then you can shut down the effect.

So these are two papers by Karl Deisseroth's group using

this technique to study the mechanism of Parkinson's disease.

And then this optical genetic system are not the only system.

There are some other system as well.

One system developed by Gero Miesenbock

in 2005 in a fruit fly is to deplete

the neuronal ATP first and then in the motor

neuron in one side of the body of fruit fly.

And then he put in caged ATP into these motor neurons.

And then he will break the cage with certain wavelengths of light,

and then with the breakage of the cage, the ATP get released so

these motor neuron get activated.

And because he only transfer these caged ATP

into one side of the motor neuron in fruit fly body,

so he can control the movement direction by this technique.

In that paper he gave it a fancy name called remote control of the fruit fly.

And then there's another system, developed by Kramer,

Isacoff, and Trauner in 2004.

They use a potassium channel and then before activation,

this potassium channel is blocked by a chemical and

this chemical has a linker with the channel.

And then with the UV light, the conformation of the linker changed and

then to pull off this blocking molecule and then this channel become open.

So this is another system.

3.3.6 Parkinson’s disease: treatment

Advanced Neurobiology I

Rencontrer les enseignants